Pregnyl (Chorionic Gonadotropin) is commonly used in reproductive endocrinology to support the body’s reproductive hormone balance when it may be deficient. It is applied across several specific clinical situations that involve systemic imbalance to support essential reproductive functions and encourage appropriate hormonal development.

Addressing Infertility Caused by Anovulation

This medication is generally used in women undergoing fertility treatments who experience anovulation (the symptom of not releasing a mature egg). Its therapeutic benefit assists with triggering ovulation, supporting the final maturation and timely release of the egg, which is necessary for conception attempts or controlled fertility processes.

---

Supporting Male Reproductive Function

Pregnyl is relevant for men with hypogonadotropic hypogonadism, a condition marked by inadequate stimulation of the testes, resulting in symptoms of low testosterone and insufficient sperm production. The key benefit supports stimulating the testes to produce natural testosterone and promote spermatogenesis (sperm creation), which may be part of symptomatic management for fertility concerns.

---

Promoting Pediatric Development

The medication is considered relevant in specific pediatric contexts, such as addressing prepubertal cryptorchidism (undescended testes) when the condition is linked to a hormonal signal deficiency rather than a physical obstruction. In these cases, the treatment may provide the hormonal signal that assists with testicular descent and supports appropriate development.

---

Quick Fact: Support for Hormonal Deficiency Pregnyl assists in providing a necessary hormonal stimulus, which contributes to easing the overall symptom load related to reproductive and developmental hormone deficits.

Eligibility Map: Who can and cannot use Прегнил — Official Regulatory Information

The eligibility profile for Pregnyl (Chorionic Gonadotropin) is strictly defined by regulatory documents, distinguishing between approved populations, absolute contraindications, and populations requiring caution or specialized monitoring.

Populations and Conditions for Use

Classification	Status According to Regulatory Labeling
Populations Allowed	Women with specific infertility or anovulation; Men with hypogonadotropic hypogonadism; Prepubertal boys with cryptorchidism not due to anatomical obstruction.
Age-Related Rules	Use in infants (below age 4) and older adults (aged 65 and over) is not established due to limited data. Prepubertal boys require monitoring for precocious development.
Pregnancy/Lactation	Contraindicated once pregnancy is established and during lactation.

---

Absolute Contraindications (Prohibited Use)

This medication must not be used in patients with the following conditions:

• Prior Hypersensitivity Reactions to the hormone or excipients.
• Sex Hormone-Dependent Tumors (including breast, prostate, ovary, or uterus carcinoma).
• Patients with Precocious Puberty or Uncontrolled Non-Gonadal Endocrinopathies.
• Malformations of the reproductive organs or Uterine Fibroid Tumors incompatible with pregnancy.

Conditions Requiring Caution

Patients with cardiac failure, hypertension, renal dysfunction, epilepsy, or migraine require close supervision during treatment.

The official regulatory profile for Chorionic Gonadotropin (hCG), the active ingredient in Прегнил, is characterized by a minimal number of documented drug-drug interactions in authoritative government regulatory sources. As a biologically derived peptide hormone, its clearance pathways generally do not involve the hepatic Cytochrome P450 (CYP) enzyme system, which is a major source of pharmacokinetic interactions for small-molecule medicines.

---

Interaction Scope

Category	Official Regulatory Statement
Medicinal Interactions	No specific drug-drug, drug-food, or drug-substance interactions (e.g., alcohol, supplements, herbal products) are formally documented in the regulatory interaction sections.
Mechanistic Basis	No specific enzyme (CYP) or transporter-mediated interactions are stated in the prescribing information to alter the systemic exposure of Chorionic Gonadotropin.
Timing/Separation	No mandatory timing or separation requirements for co-administration with other medicinal products are documented based on an interaction risk.
Population-Specific Notes	No population-specific interaction considerations (e.g., related to hepatic or renal impairment) are documented in the official labeling.

---

Interaction-Related Restriction

The only specific interaction constraint formally documented by regulatory authorities is the potential for interference with laboratory assays. The administration of Chorionic Gonadotropin can result in a false-positive outcome on an immunological pregnancy test, as the substance itself is the hormone measured by the diagnostic assay. This is a formal restriction noted in the regulatory context to prevent the misinterpretation of diagnostic results.

Agonism of the Luteinizing Hormone Receptor

The drug's primary action involves acting as a full agonist at the Luteinizing Hormone/Chorionic Gonadotropin Receptor (LHCGR), a specific receptor found on cells within the gonads. This binding initiates the initial molecular cascade, bypassing the body's natural signaling to drive an acute hormonal instruction to the target cells.

Activation of the Steroidogenesis Cascade

The LHCGR activation triggers a defined intracellular sequence involving Gs protein and the second messenger cAMP, which upregulates the activity of key steroidogenic enzymes (like STAR protein). This mechanism leads directly to the substantial and sustained synthesis and release of sex hormones (progesterone or testosterone) from the gonadal tissue.

Sustained Physiological Triggering

Due to the drug's extended duration of action compared to the natural hormone, the mechanism provides a prolonged, high-level stimulus to the gonads. This sustained signaling is a prolonged hormonal drive for the physiological completion of multi-hour processes, such as the final oocyte maturation and release in the female or provides the androgen-driven hormonal signal for reproductive processes in the male.

Administration Scope

Feature	Guideline
Route of administration	Intramuscular (IM) injection only. The product is not intended for intravenous administration.
Dosing schedule	Ovulation Induction: A single dose of 5,000 to 10,000 IU is administered following a course of FSH-containing preparation. Male Hypogonadotropic Hypogonadism: Doses range from 500 to 4,000 IU per injection, following specific long-term, cyclic courses.
Frequency pattern	Single-dose (acute use for ovulation trigger) or Fixed-interval (typically two or three times per week) for long-term regimens.
Preparation requirements	The lyophilized powder must be dissolved with the accompanying sterile solvent. The vial must be agitated gently until the powder is dissolved and must not be shaken. The final solution should be visually inspected for particulates prior to administration.
Age-group administration rules	Specific dosing and course durations are established for prepubertal pediatric patients with cryptorchidism, typically involving regimens of 1,000 IU or 4,000 IU three times weekly.
Special procedural conditions	Administration must be carried out under the supervision of a physician experienced in the relevant conditions. The reconstituted solution is typically stable for up to 28 days when refrigerated (2°C–8°C).

---

Connection to the Use Protocol

Established protocols provide that this product must be administered via injection and detail the mandatory steps for powder reconstitution and inspection. Standard parameters define clear, numeric dose ranges and fixed, non-daily frequency patterns that dictate whether the treatment is a single injection or a structured, multi-month course. This protocol is restricted to administration only under the direct supervision of a specialist physician.

Research evidence / Overview of studies for Прегнил

---

Evidence for use in Male Hypogonadotropic Hypogonadism (HH)

Research has explored the use of Pregnyl in adult males with hypogonadotropic hypogonadism, a condition marked by functional limitations related to hormone production signals. Studies focused on monitoring hormonal markers and outcomes related to systemic or functional imbalance. Findings describe patterns observed in the studies related to these changes. Comparative evidence is lacking in some areas, and follow-up durations were limited, meaning long-term patterns are not fully established.

Evidence for use in Prepubertal Cryptorchidism

Pregnyl was evaluated in studies involving prepubertal patients with undescended testicles, with research examining patterns related to the testicle's descent. The data describe patterns observed related to the physical outcomes being monitored. However, sample sizes were modest in some studies, and evidence quality varies across studies, meaning that certainty remains low in some aspects of the research.

Evidence for use in Selected Female Fertility Treatments

Pregnyl was studied for its role in controlled ovarian stimulation cycles for women with conditions marked by functional limitations related to fertility. Studies explored how the timing of Pregnyl was associated with outcomes where ovulation was observed and final stages of egg maturation were monitored. Subgroup findings are uncertain when looking at specific patient characteristics, and comparative evidence is lacking against all alternative options.

---

Long-term studies and follow-up

Research concerning the extended impact of Pregnyl is a critical area, but long-term effects are not fully established. Follow-up durations were limited in many trials, and there is limited information for long-term outcomes that monitor changes over an extended time interval after the study period.

---

Evidence in special populations

Research has examined the use of Pregnyl in children (e.g., cryptorchidism) and adults. However, the data for certain groups remain insufficient. Evidence relating to patients with comorbid conditions or older adults is limited, and subgroup findings are uncertain in these populations.

---

What is still uncertain about Прегнил (Pregnyl)

Key gaps include that comparative evidence is lacking to fully understand its patterns of response versus alternative options. The long-term effects are not fully established due to limited follow-up durations. The findings were mixed in some studies, highlighting that evidence quality varies across studies, and more research is needed. Overall, research is ongoing and the evidence base highlights what is known — and what is still uncertain.

Key Studies & References Use of exogenous gonadotropins for ovulation induction in anovulatory women: a committee opinion (2020) (ASRM Guideline)

Common questions about Прегнил (FAQ)

Q: Does Прегнил treat the underlying cause or just the symptoms?

Official information describes this medication as a gonadotropin, meaning it acts as a substitute for the body's natural Luteinizing Hormone (LH). This action stimulates the production of sex hormones or triggers essential physiological processes, such as ovulation. Its role is to support and manage specific reproductive functions that may be limited by a hormonal deficiency.

Q: How long does the effect of one dose of Прегнил last in the body?

Regulatory information on the pharmacokinetics of Chorionic Gonadotropin indicates that the substance has a relatively long half-life, which is the time it takes for half the drug to be eliminated from the body. This half-life is described as approximately 30 to 40 hours. This mechanism is designed to provide a sustained stimulus to the target reproductive cells over a period of several days following a single administration.

Q: What does the available research say about the long-term use of Прегнил?

The evidence base for this medication includes studies that examine its use in various conditions. According to the research overview, follow-up durations have often been limited, meaning the long-term effects and outcomes over many years are not fully established. This highlights the scientific understanding that more research is needed to fully establish long-term patterns.

Q: What is the general duration of treatment cycles involving Прегнил?

Regulatory documents describe the use of this drug in two general patterns. In some cases, such as in certain female fertility treatments, it is administered as a single, acute injection. For other conditions, like hormone support in males, it is described as being used in fixed-interval, multi-month or cyclic courses.

Q: What kind of monitoring or tests are typically required during Прегнил treatment?

The official instructions for use specify that close supervision is required, particularly when the drug is used for ovarian stimulation. Monitoring often involves regular transvaginal ultrasound examinations and laboratory tests of hormone levels, such as serum estradiol. These steps are specified in the official prescribing information for monitoring the progress of the treatment.

Q: Is Прегнил considered a type of hormone replacement?

The drug's active substance is Chorionic Gonadotropin, which is chemically classified as a gonadotropin. Functionally, it acts to stimulate the body’s own production of sex hormones or substitutes the natural Luteinizing Hormone (LH) signal. The official profile describes its role in triggering or supporting a hormonal process.

Q: What is the difference between Прегнил and other fertility-related medications?

This medication is classified as a Chorionic Gonadotropin (hCG) and is primarily known for acting like Luteinizing Hormone (LH). In fertility treatments, it is often used as a specific trigger to initiate the final phase, such as ovulation, usually following an earlier course of treatment with Follicle Stimulating Hormone (FSH)-containing preparations.

Q: Does Прегнил cause mood swings or changes in emotion?

Official safety information lists several adverse reactions related to the nervous system and psychiatric health. These formally documented effects include Irritability, Restlessness, and Depression. Changes in mood or emotion are among the effects listed, and the official safety profile should be reviewed with a healthcare provider.

Q: Is weight gain a potential side effect of Прегнил?

The official list of side effects includes Edema, which is fluid retention. Furthermore, rapid weight gain is specifically noted in the regulatory documents as an early warning sign of Ovarian Hyperstimulation Syndrome (OHSS), a serious adverse reaction associated with this class of medication.

Q: Can Прегнил be taken with common pain relievers like ibuprofen?

The regulatory sections that detail drug interactions state that there are no specific drug-drug interactions formally documented for Chorionic Gonadotropin. This means that official product information does not list mandatory restrictions regarding co-administration with other medicines, including common pain relievers like ibuprofen.

Q: Are there any specific vitamins or supplements that interact with Прегнил?

Based on the official product information, no specific interactions with food, supplements, or herbal products are formally documented. The official regulatory interaction sections generally lack mandated timing or separation requirements for co-administration with these products.

Q: Can people with thyroid problems use Прегнил?

Regulatory documents state that this medication must not be used (is contraindicated) in patients with uncontrolled non-gonadal endocrinopathies. The official contraindication applies to uncontrolled disorders of the endocrine glands, which includes conditions affecting the thyroid or adrenal gland.

Q: Is Прегнил approved for use in children or adolescents?

The official indications for this drug include use in prepubertal boys (before puberty starts) for the treatment of cryptorchidism, provided it is not due to a physical obstruction. However, regulatory information notes that use in infants below the age of four is not established due to limited data.

Q: Does using Прегнил affect athletic performance or appear on doping tests?

For male athletes, the active substance, Chorionic Gonadotropin, is classified as a prohibited substance under the rules of the World Anti-Doping Agency (WADA). It falls under the category of peptide hormones, growth factors, and related substances.

Q: What is the risk of developing an allergic reaction to Прегнил?

Official safety documents state that anaphylaxis (a severe, life-threatening allergic reaction) and generalized hypersensitivity reactions have been reported with the use of gonadotropins. These reactions are formally documented as serious adverse reactions.

Q: Can Прегнил cause headaches or migraines?

Headache is listed as one of the commonly reported adverse reactions in the official safety profile. Furthermore, the official prescribing information notes that individuals with a history of conditions like migraine require close supervision during the course of treatment.

Q: Is it necessary to adjust my diet while on Прегнил therapy?

According to the official regulatory documents, no mandatory timing or separation requirements regarding the co-administration of this drug with food or drinks are documented based on a risk of interaction. The official interaction scope does not mandate specific dietary adjustments.

Q: Is the side effect profile different for men versus women?

Yes, the official safety documentation lists side effects that are specific to each population, which establishes a different overall safety profile. Examples include Gynecomastia (breast enlargement) in males, and Ovarian Hyperstimulation Syndrome (OHSS) in females.

Q: Why is Прегнил sometimes associated with risk of blood clots?

The official safety labeling formally reports the risk of thromboembolic events, which are the formation of blood clots. This risk is noted to occur particularly in women with pre-existing risk factors for thrombosis, and it is often associated with cases of Ovarian Hyperstimulation Syndrome (OHSS).

Q: Can I travel with Прегнил, and are there specific packing requirements?

When traveling, the drug's storage requirements must be maintained. The unmixed powder should be kept at controlled room temperature, typically between 15 C and 30 C. The solution once mixed (reconstituted) must be stored in a refrigerator, at temperatures between 2 C and 8 C, to maintain its stability.

Q: What should I do if the mixed solution looks cloudy?

Official administration instructions require the solution to be visually inspected after mixing. The instructions specify that the reconstituted solution must appear clear and colorless. If the solution is found to be cloudy or to contain any particles, the regulatory documentation specifies that it must not be used.

Q: Is it true that Прегнил can be used for weight loss (excluding forbidden off-label claims)?

Regulatory information for the drug explicitly states that the active ingredient, Chorionic Gonadotropin, has not been demonstrated to be effective as an adjunctive therapy in the treatment of obesity. Its approved uses are strictly limited to the conditions specified in the official labeling.

Storage and Disposal of Pregnyl (Chorionic Gonadotropin)

Pregnyl must be stored under specific, labeled conditions to maintain its stability.

Product State	Temperature Requirement	Stability Constraint
Unmixed Powder	Store at Controlled Room Temperature (15 C to 30 C or 59 F to 86 F).	Protect from light and moisture. Do not freeze.
Reconstituted Solution	Store in a refrigerator (mathbf2 C to mathbf8 C or mathbf36 F to mathbf46 F).	Stable for up to 60 days; must be discarded thereafter.

All medication must be stored in the original packaging, and it must be kept out of the reach and sight of children. Used needles and syringes must be immediately placed in a rigid, puncture-resistant sharps container. Follow all state and local laws for the proper disposal of the full sharps container and any unused or expired medicine.